Welcome to the 4th In Vivo Cell Engineering & Gene Editing Summit, the only in vivo dedicated event designed to progress cell and gene therapies to the next frontier.

This summit provides you with exclusive insights into pioneering IND enabling and clinical data, delivery technologies and effective clinical trial designs. Alongside all of this, our speaker faculty will explore regulatory and inter-governmental requirements to accelerate your clinical pipeline.

This year's experts include C-suite executives, VPs and Directors from Myeloid Therapeutics, Ensoma, Capstan Therapeutics, Editas Medicines, AbbVie, Intellia Therapeutics, Umoja Biopharma and many more!

Biotech and pharma companies are shifting from ex vivo to in vivo therapies due to their improved efficiency, accessibility and cost-effectiveness. With this in mind, this event is a must-attend for those looking to pioneer in this evolving field.

Event link here.